• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • Samples
    • MRI Images
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

New paper investigating the prediction of Alzheimer’s disease biomarker status

2020-11-12News

The EPAD team has published a new paper entitled “Prediction of Alzheimer’s disease biomarker status defined by the ‘ATN framework’ among cognitively healthy individuals: results from the EPAD longitudinal cohort study” in the journal Alzheimer’s Research Therapy.

In this paper, authors from the University of Oxford and the Alzheimer Center Amsterdam tested the predictive utility of validated composite risk scores in their association with the Amyloid/Tau/Neurodegeneration (ATN)-defined biomarker group status in a cognitively healthy ageing sample drawn from the EPAD longitudinal cohort study (LCS). The main aim was to investigate independent risk factors for Alzheimer’s disease (AD) and vascular-related composite risk scores, in relation to prediction of ATN pathology.
The sample is drawn from 1,500 adult participants aged over 50 years from EPAD LCS (dataset V1500.0). It recruited participants across 21 European sites across the full range of anticipated probability for AD development.

 

Abstract:

Background: The Amyloid/Tau/Neurodegeneration (ATN) framework has been proposed as a means of evidencing the biological state of Alzheimer’s disease (AD). Predicting ATN status in pre-dementia individuals therefore provides an important opportunity for targeted recruitment into AD interventional studies. We investigated the extent to which ATN-defined biomarker status can be predicted by known AD risk factors as well as vascular-related composite risk scores.

Methods: One thousand ten cognitively healthy older adults were allocated to one of five ATN-defined biomarker categories. Multinomial logistic regression tested risk factors including age, sex, education, APOE4, family history of dementia, cognitive function, vascular risk indices (high systolic blood pressure, body mass index (BMI), high cholesterol, physical inactivity, ever smoked, blood pressure medication, diabetes, prior cardiovascular disease, atrial fibrillation and white matter lesion (WML) volume), and three vascular-related composite scores, to predict five ATN subgroups; ROC curve models estimated their added value in predicting pathology.

Results: Age, APOE4, family history, BMI, MMSE and white matter lesions (WML) volume differed between ATN biomarker groups. Prediction of Alzheimer’s disease pathology (versus normal AD biomarkers) improved by 7% after adding family history, BMI, MMSE and WML to a ROC curve that included age, sex and APOE4. Risk composite scores did not add value.

Conclusions: ATN-defined Alzheimer’s disease biomarker status prediction among cognitively healthy individuals is possible through a combination of constitutional and cardiovascular risk factors but established dementia composite risk scores do not appear to add value in this context.

You can read the open-access article here: http://dx.doi.org/10.1186/s13195-020-00711-5

 

Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Closing EPAD article published in the Alzheimer Europe magazine
2021-02-24
Alzheimer Europe launches a report on data sharing in dementia research
2021-02-23
Local actions to keep the EPAD Longitudinal Cohort data collection going
2021-02-17
Neuronet releases its Knowledge Base dashboard
2021-02-01
The final EPAD dataset is now available to the entire research community
2020-11-30
ALZFORUM
Alzforum conference blog mentions EPAD
2020-11-30
Latest News
  • Closing EPAD article published in the Alzheimer Europe magazine
    2021-02-24
  • Alzheimer Europe launches a report on data sharing in dementia research
    2021-02-23
  • Local actions to keep the EPAD Longitudinal Cohort data collection going
    2021-02-17
  • Neuronet releases its Knowledge Base dashboard
    2021-02-01
  • The final EPAD dataset is now available to the entire research community
    2020-11-30
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

Have a look on the @RosetreesT workshop on neurodegenerative diseases. @craig_ritchie68 presented @IMI_EPAD & @AD_PREVENT (from 1:06:00). @brainhealthscot @AlzData youtu.be/PsAZ1T5MmBo twitter.com/brainhealthsco…

reply retweet favorite
8:01 am · 2021-03-04
Twitter
EPAD
EPAD
@IMI_EPAD

The latest @AlzheimerEurope #newsletter includes an article on the first local @IMI_EPAD community meeting held last month among the Scottish research sites and collaborators who have been involved in the EPAD Longitudinal Cohort Study. Read more here: bit.ly/Feb2021AEnews twitter.com/AlzheimerEurop…

reply retweet favorite
3:26 pm · 2021-03-03
Twitter
EPAD
EPAD
@IMI_EPAD

@AD_PREVENT @alzassociation @alzheimerssoc Congratulations to all the team 👏

reply retweet favorite
7:03 am · 2021-03-01
Twitter
EPAD
EPAD
@IMI_EPAD

.@AlzheimerEurope has published a new edition of its “Dementia in Europe” magazine. It includes a closing article on @IMI_EPAD. Our co-leads @craig_ritchie68 and Serge Van der Geyten, reflect on the achievements of the project. Download the PDF here: bit.ly/DementiaInEuro… twitter.com/AlzheimerEurop…

reply retweet favorite
12:40 pm · 2021-02-24
Twitter
EPAD
EPAD
@IMI_EPAD

Last week, we held the first local @IMI_EPAD community meeting among the Scottish research sites, collaborators, academics & scientists who have been involved in our Longitudinal Cohort Study and now continue to contribute to the study locally More info⤵️ ep-ad.org/2021/02/17/loc… pic.twitter.com/MTKmanCURk

reply retweet favorite
6:51 am · 2021-02-24
Copyright © 2015-19 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.